Radio Advisory Advisory Board

The healthcare industry has been rocked by the pandemic and thrown headfirst into a new era of technological and therapeutic revolution. Yet, in the midst of all this change and uncertainty, healthcare leaders are expected not just to survive, but actually drive value for their organizations, patients, and communities. The problem is, “driving value” is not only complex, but it’s also ambiguous. Leaders who talk about value across the industry may not even be talking about the same thing. So, how should the industry think about driving value and what does it take to get this right?


In this episode, live from Advisory Board’s 2024 Value Summit, host Abby Burns invites Stacey Richter, healthcare entrepreneur, co-president of Aventria Health Group, and host of the Relentless Health Value podcast, to break down what “value” in healthcare actually means, where organizations go wrong, and how we can work to improve value across the industry.


Links:



Raising the Value Bar Virtual Summit
Our Value-Based Care playlist
EP358: How Health Insurance Plan Design Can Lead to Patients Sacrificing Needed Care, Their Mental Health, and (Sometimes) Buying Groceries, With Wayne Jenkins, MD | Relentless Health Value™
EP391: Lessons for Private Equity and Others Trying to Do Right by PCPs and Their Patients, With Scott Conard, MD | Relentless Health Value™
EP427: How Do Digital Health Vendors Deliver Patient Outcomes and Experiences? With Rik Renard | Relentless Health Value™
EP432: The Knifepoint Intersection of Margin and Mission and the Peril of Cutting Clinical “Waste,” With Kate Wolin, ScD | Relentless Health Value™





The challenges with migraine care — and what health systems can do about it





A transcript of this episode as well as more information and resources can be found on radioadvisory.advisory.com.

The rise of generative AI has impacted healthcare in many ways – one of which is that it’s pushing Big Tech toward becoming not just a relevant, but a central player in the industry. And when we’re talking Big Tech, we have to include Google. Google’s activity in healthcare has been turbulent since it entered the space nearly two decades ago, but it’s impossible to deny the significance of the contributions it’s made to the industry.


Now with the rapid growth of genAI, Google is refining its healthcare strategy to drive maximum impact in the areas it’s best positioned to – places like consumer, therapeutics, diagnostics, and more.


At the forefront of this work is Dr. Karen DeSalvo, Google’s Chief Health Officer. This week, guest host Eric Larsen, President Emeritus of Advisory Board and President of Towerbrook Advisors sits down with Dr. DeSalvo to unpack the seemingly boundless opportunities of generative AI to evolve healthcare and the unique—and scoped—role Google is playing in helping advance that evolution.


Links:



Lessons from the C-suite
AI in healthcare: Insights from 10 C-suite executives
Ep. 197: Lessons from the C-Suite: Demystifying generative AI with Dr. John Halamka, President of Mayo Clinic Platform
Ep. 185: AI adoption: why you can't afford to "wait and see"
Ep. 180: Tom Lawry on why AI has a PR problem





The chronic condition we should be talking about: Challenges and opportunities in migraine care





Learn about Advisory Board Fellowship





A transcript of this episode as well as more information and resources can be found on radioadvisory.advisory.com.

So far in our series on bespoke care and innovation, we’ve delved into the future of cancer care and the opportunities for equity in precision medicine. But we can’t conclude our series without talking about one of the most exciting developments in the field: cell and gene therapies. We’ve talked about these therapies on the pod before—but like everyone else, we’ve primarily focused on the payment side of the equation and looked at how purchasers and pharma can work together to ensure patient access. These conversations miss the voice of a key stakeholder: providers.


What is the role of the provider organizations in realizing the value of cell and gene therapies? To answer that question, in the final episode of our series leading up to Advisory Board’s Clinical Innovation Summit: Revolutions in Specialty Care, host Rachel (Rae) Woods invites Advisory Board pharmacy experts Gina Lohr and Chloe Bakst to unpack how providers are grappling with how to get these life-changing treatments to those that need them.


Links:



Ep. 210: How you approach precision medicine matters—for some patients more than others
Ep. 209: Predicting what oncology will look like in 2030

4 things leaders need to know about high-cost drugs





3 takeaways on why primary care is key to migraine management





Register for the Revolutions in Specialty Care Summit





A transcript of this episode as well as more information and resources can be found on radioadvisory.advisory.com.

It's no secret that healthcare is becoming more and more personalized – or “bespoke” – as increasingly sophisticated diagnostics and therapeutics continue to explode into the market. This vast pipeline is redefining the industry in several ways—but there is real risk associated if the stakeholders responsible for developing, delivering, and paying for these innovations aren’t baking health equity into their business models.


Last week, in the first episode of our run up to the Advisory Board Clinical Innovation Summit: Revolutions in Specialty Care, we discussed Advisory Board’s prediction for the future of oncology. This week, host Rachel (Rae) Woods invites Advisory Board experts Amanda Okaka and Fanta Cherif to break down the health equity conundrum presented by precision medicine: Will precision medicine reduce health disparities, or exacerbate them? The answer depends on the actions—big and small—of industry leaders.


Links:



Register for the Revolutions in Specialty Care Summit
How precision medicine can help us move from race-based to race-conscious medicine
Ep. 209: Predicting what oncology will look like in 2030
Ep. 204: Unveiling "Bespoke Care": Healthcare's tailored future
Bespoke care, part 1: What it is and how it’s transforming care delivery





Register for the Clinical Innovation Summit





A transcript of this episode as well as more information and resources can be found on radioadvisory.advisory.com.

There has been a lot of change in the oncology space in the last few years. These changes have brought new pressures, like workforce strain, increased competition, rising spend, and more. While many leaders are worried about the "right now," it is crucial to consider how you can best position yourself for the future of cancer care.


That's why, in this episode, host Rachel (Rae) Woods invites Advisory Board specialty care experts Lindsey Paul and Julia Elder to discuss why preparing for the future means making changes today. Throughout the conversation, they discuss how current pressures are changing the field of oncology and four ways cancer care will change by 2030.


Links:



4 predictions for cancer care in 2030
3 strategies to leverage oncology pharmacists and improve cancer care
5 strategies to deploy (and empower) APPs in cancer care
Ep. 203: Value series: Is the future of VBC in specialty care? Zing Health & Strive Health say yes.
Ep. 202: Value series: Why CenterWell (and Humana) is going all in on senior care





Register for the Clinical Innovation Summit





A transcript of this episode as well as more information and resources can be found on radioadvisory.advisory.com.

According to economist Jim Rebitzer and healthcare consultant Bob Rebitzer, the healthcare industry has failed in achieving what many other sectors have accomplished – improving products, while simultaneously reducing costs over time.


In this episode, recorded live at The Players 2024 Championship, host Rachel (Rae) Woods invited Jim and Bob to discuss the central premise of their book, Why Not Better and Cheaper? They discussed the root causes of this challenge – including incentives, prevailing professional and social norms, and competition – that the industry must confront to deliver better and cheaper healthcare.


Links:



Learn more about the Rebitzer brothers and their new book, Why Not Better and Cheaper?
Our Financial Impact playlist
This spring Radio Advisory is celebrating four years of production. Thank you for listening!
Truly personalized care is possible. Here's how to make it a reality.





Learn about Advisory Board On-Demand Courses





Learn about Advisory Board Fellowship





A transcript of this episode as well as more information and resources can be found on radioadvisory.advisory.com.